Asian Pacific journal of cancer prevention : APJCP · 2026
Development and Validation of a One-Step Multiplex RT-qPCR Assay for BCR-ABL1 Transcript Detection and Monitoring in Moroccan Chronic Myeloid Leukemia Patients.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Benchrifa Abdenacer, Albanyahyati Basma, Balouiri Mounyr, El Hadi Hicham, Bakri Youssef, Doghmi Kamal, Moumen Abdeladim
Аннотация
OBJECTIVE: Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion gene. Molecular monitoring of this transcript is essential for patient management. However, the high cost of imported assays limits access to regular monitoring in Morocco.
METHODS: We developed and validated a cost-effective one-step multiplex RT-qPCR assay that simultaneously detects BCR-ABL1 and ABL1 transcripts in peripheral blood mononuclear cells. Samples from 63 Moroccan CML patients were analyzed and compared with the GeneXpert system.
RESULT: The assay showed efficiencies above 95% and R2 ≥ 0.99 for both targets. BCR-ABL1/ABL1 ratios correlated strongly with GeneXpert (r = 0.93, p < 0.001) and showed 86% overall agreement.
CONCLUSION: This locally developed assay is a reliable and affordable alternative for routine BCR-ABL1 detection and monitoring, improving access to molecular testing in resource-limited settings.
METHODS: We developed and validated a cost-effective one-step multiplex RT-qPCR assay that simultaneously detects BCR-ABL1 and ABL1 transcripts in peripheral blood mononuclear cells. Samples from 63 Moroccan CML patients were analyzed and compared with the GeneXpert system.
RESULT: The assay showed efficiencies above 95% and R2 ≥ 0.99 for both targets. BCR-ABL1/ABL1 ratios correlated strongly with GeneXpert (r = 0.93, p < 0.001) and showed 86% overall agreement.
CONCLUSION: This locally developed assay is a reliable and affordable alternative for routine BCR-ABL1 detection and monitoring, improving access to molecular testing in resource-limited settings.